BioSante Pharmaceuticals, Inc. (BPAX) sent a letter to stockholders recommending that stockholders vote "FOR" the proposed merger with ANI Pharmaceuticals Inc. The BioSante board strongly believes the proposed merger is the best alternative for stockholders.
If the merger isn't approved, BioSante will remain a stand-alone company and will still need to address the issues and risks that led it to propose the merger with ANI in the first place, the company stated. The board believes the merger would create more value for its stockholders in the long-term than BioSante could create as an independent, stand-alone company.
Upon completion of the merger, the combined company will be renamed ANI Pharmaceuticals, Inc. and will operate under the leadership of the ANI management team, with Arthur Przybyl serving as president and chief executive officer.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.